476 related articles for article (PubMed ID: 19036624)
1. The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions.
Girard J
Diabetes Metab; 2008 Dec; 34(6 Pt 1):550-9. PubMed ID: 19036624
[TBL] [Abstract][Full Text] [Related]
2. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
Escalada FJ
Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458
[TBL] [Abstract][Full Text] [Related]
3. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes.
Gautier JF; Choukem SP; Girard J
Diabetes Metab; 2008 Feb; 34 Suppl 2():S65-72. PubMed ID: 18640588
[TBL] [Abstract][Full Text] [Related]
4. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
5. Incretin hormones: Their role in health and disease.
Nauck MA; Meier JJ
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
[TBL] [Abstract][Full Text] [Related]
6. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
7. New physiological effects of the incretin hormones GLP-1 and GIP.
Asmar M
Dan Med Bull; 2011 Feb; 58(2):B4248. PubMed ID: 21299928
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 and control of insulin secretion.
Thorens B
Diabete Metab; 1995 Dec; 21(5):311-8. PubMed ID: 8586147
[TBL] [Abstract][Full Text] [Related]
9. [The concept of incretins and the physiological roles of incretins].
Kawamori R
Nihon Rinsho; 2011 May; 69(5):761-9. PubMed ID: 21595259
[TBL] [Abstract][Full Text] [Related]
10. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
[TBL] [Abstract][Full Text] [Related]
11. RD Lawrence Lecture 2017 Incretins: the intelligent hormones in diabetes.
Gault VA
Diabet Med; 2018 Jan; 35(1):33-40. PubMed ID: 29044772
[TBL] [Abstract][Full Text] [Related]
12. Incretin hormones and type 2 diabetes.
Nauck MA; Müller TD
Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
[TBL] [Abstract][Full Text] [Related]
13. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
14. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.
Ranganath LR
J Clin Pathol; 2008 Apr; 61(4):401-9. PubMed ID: 18375745
[TBL] [Abstract][Full Text] [Related]
15. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.
Pederson RA; Satkunarajah M; McIntosh CH; Scrocchi LA; Flamez D; Schuit F; Drucker DJ; Wheeler MB
Diabetes; 1998 Jul; 47(7):1046-52. PubMed ID: 9648827
[TBL] [Abstract][Full Text] [Related]
16. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Finan B; Ma T; Ottaway N; Müller TD; Habegger KM; Heppner KM; Kirchner H; Holland J; Hembree J; Raver C; Lockie SH; Smiley DL; Gelfanov V; Yang B; Hofmann S; Bruemmer D; Drucker DJ; Pfluger PT; Perez-Tilve D; Gidda J; Vignati L; Zhang L; Hauptman JB; Lau M; Brecheisen M; Uhles S; Riboulet W; Hainaut E; Sebokova E; Conde-Knape K; Konkar A; DiMarchi RD; Tschöp MH
Sci Transl Med; 2013 Oct; 5(209):209ra151. PubMed ID: 24174327
[TBL] [Abstract][Full Text] [Related]
17. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
[TBL] [Abstract][Full Text] [Related]
18. [Incretin and bone].
Yamada Y
Clin Calcium; 2009 Sep; 19(9):1312-7. PubMed ID: 19721203
[TBL] [Abstract][Full Text] [Related]
19. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
Escalada FJ
Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836
[TBL] [Abstract][Full Text] [Related]
20. Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?
Holst JJ
BioDrugs; 2002; 16(3):175-81. PubMed ID: 12102645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]